Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Total Current Liabilities (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Total Current Liabilities for 16 consecutive years, with $13.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 12.42% to $13.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.6 million, a 12.42% increase, with the full-year FY2024 number at $15.6 million, up 44.97% from a year prior.
  • Total Current Liabilities was $13.6 million for Q3 2025 at Plus Therapeutics, up from $7.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $18.8 million in Q2 2024 to a low of $4.9 million in Q1 2022.
  • A 5-year average of $10.6 million and a median of $10.5 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 160.03% in 2023, then plummeted 61.06% in 2025.
  • Plus Therapeutics' Total Current Liabilities stood at $9.5 million in 2021, then increased by 24.92% to $11.9 million in 2022, then decreased by 9.49% to $10.7 million in 2023, then skyrocketed by 44.97% to $15.6 million in 2024, then dropped by 12.44% to $13.6 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Total Current Liabilities are $13.6 million (Q3 2025), $7.3 million (Q2 2025), and $10.6 million (Q1 2025).